Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - What's Next?

Key Points

• Pharming Group experienced a significant increase in trading volume, with approximately 18,207 shares traded, representing a 158% rise from the previous session.
• The company reported $0.06 earnings per share for the last quarter, exceeding analysts' expectations of ($0.10), alongside a revenue of $93.20 million.
• An institutional investor recently acquired 2,979 shares of Pharming Group, highlighting growing interest among hedge funds in the biopharmaceutical firm.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 18,207 shares were traded during trading, an increase of 158% from the previous session's volume of 7,054 shares.The stock last traded at $15.04 and had previously closed at $14.83.

Pharming Group Price Performance

The stock has a market capitalization of $1.01 billion, a P/E ratio of -113.31 and a beta of 0.05. The business has a fifty day simple moving average of $12.59 and a 200-day simple moving average of $10.63. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The company had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.